Canada’s Drug Agency (CDA-AMC) recommends that Blincyto be reimbursed by public drug plans for the treatment of patients with Philadelphia chromosome (Ph)–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy if certain conditions are met.
